Adverse events: hypertension · patients with Guillain‐Barré syndrome
Corticosteroid leads to lower adverse events ‐ hypertension compared with control (high certainty).
1 finding from 1 review
Primary: adverse events ‐ burning/itching at application site · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment showed no clear difference in primary: adverse events ‐ burning/itching at application site compared with vehicle (moderate certainty).
1 finding from 1 review
Intervention not reported
Total number of adverse events · children with chronic asthma
The intervention showed no clear difference in total number of adverse events (high certainty).
1 finding from 1 review
Intervention not reported
Total number of adverse events · children with chronic asthma
The intervention showed no clear difference in total number of adverse events (moderate certainty).
1 finding from 1 review
Other adverse events Short‐term · Adults with plantar heel pain¹
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events 49 weeks · adults with asthma
The intervention showed no clear difference in serious adverse events 49 weeks (low certainty).
1 finding from 1 review
Serious adverse events 17 weeks · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in serious adverse events 17 weeks compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Serious adverse events 22 weeks · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in serious adverse events 22 weeks compared with long‐acting beta2‐agonists (LABA) add‐on (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ recurrent fever · acute bacterial meningitis
The intervention probably leads to higher adverse events ‐ recurrent fever (moderate certainty).
1 finding from 1 review
Adverse events ‐ nasopharyngitis, including sore throat · patients with severe chronic rhinosinusitis with nasal polyps
Anti‐IL‐4Rα mAb (dupilumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat (longest… compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
Serious adverse events ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events during treatment · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes serious adverse events during treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Non‐fatal, serious adverse events (all) · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in non‐fatal, serious adverse events (all) (moderate certainty).
1 finding from 1 review
Intervention not reported
Non‐fatal, serious adverse events (all) · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in non‐fatal, serious adverse events (all) (high certainty).
1 finding from 1 review
All‐cause serious adverse events 24 weeks · adults with asthma not well controlled on ICS
LAMA add‐on showed no clear difference in all‐cause serious adverse events 24 weeks compared with ICS alone (low certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol · adults with eczema
1 finding from 1 review
Non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in all‐cause non‐fatal serious adverse events compared with same‐dose ICS (high certainty).
1 finding from 1 review
Non‐fatal serious adverse events · children and adolescents with chronic asthma
Regular formoterol and ICS showed no clear difference in all‐cause non‐fatal serious adverse events compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in asthma‐related non‐fatal serious adverse events compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · children and adolescents with chronic asthma
It is very uncertain whether regular formoterol and ICS changes asthma‐related non‐fatal serious adverse events compared with same‐dose ICS (very low certainty).
1 finding from 1 review